Dr. Bazhenova on the Treatment Landscape of Non-Driver NSCLC

In part 1, experts explores how assessing individual risk factors is crucial in selecting the appropriate JAK inhibitor for patients with myelofibrosis.

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

Before the emergence of data from the SUNLIGHT trial, there were only 2 options for therapy in advanced colorectal cancer: trifluridine/tipiracil and regorafenib.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Experts developed consensus recommendations through the modified Delphi process for metastatic prostate cancer management during the 2024 US Prostate Cancer Conference.

In an interview with Peers & Perspectives in Oncology, John L. Marshall, MD, discussed treatment approaches and sequencing for refractory colorectal cancer.